Skip to main content
Top

26-05-2022 | Insulin glargine | News

News in brief

Real-world support for adding Gla-300 to GLP-1 receptor agonists in type 2 diabetes

Author: Alba Ruzafa

print
PRINT
insite
SEARCH

medwireNews: The addition of insulin glargine 300 units/mL (Gla-300) to glucagon-like peptide (GLP)-1 receptor agonist therapy in people with type 2 diabetes results in improved glycemic control without increasing risk for hypoglycemia, suggest findings from the real-world DELIVER-G study.

“This is highly clinically relevant in the context of [people with type 2 diabetes] starting with GLP-1 [receptor agonists] and adding [basal insulin], as most previous studies have assessed the addition of GLP-1 [receptor agonists] to [basal insulin] therapy,” say Timothy Bailey (AMCR Institute, Escondido, California, USA) and fellow authors.

The retrospective study, published in Diabetes, Obesity and Metabolism, included data from 271 insulin-naïve people (mean age 57.9 years) on daily or weekly GLP-1 receptor agonist therapy who required treatment intensification and initiated Gla-300 between 2015 and 2019.

After a 6-month follow-up period, there was a significant reduction in mean glycated hemoglobin (HbA1c), from 9.16% (77 mmol/mol) to 8.19% (66 mmol/mol), with the addition of Gla-300. This reduction was irrespective of daily or weekly GLP-1 receptor agonist use or HbA1c level at baseline.

There was also a significant increase in the percentage of individuals who achieved HbA1c control during the follow-up period compared with baseline, with an increase of 17.34 percentage points for a target of under 7% (53 mmol/mol) and 31.73 percentage points for under 8% (64 mmol/mol).

The team says that there were no changes in the overall incidence or event rate of hypoglycemia after adding Gla-300.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group

Diabetes Obes Metab 2022; doi:10.1111/dom.14739

print
PRINT

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »